The Motley Fool

Is AstraZeneca plc A Better Buy Than BTG plc, Dechra Pharmaceuticals plc And Genus plc?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Despite being in the midst of coming to terms with the loss of several key, blockbuster drugs, shares in AstraZeneca (LSE: AZN) (NYSE: AZN.US) have performed remarkably well in recent years. For example, after hitting a low of £25.92 in June 2012, they have risen by over 70% in just three years. That’s a stunning rate of growth and, while at least part of that has been a result of bid rumours and bid approaches, it shows that investors in the company are looking at the long term future for the business, rather than its present performance.

Future Potential

Clearly, AstraZeneca remains a long way off its previous levels of profitability. For example, even back in 2011 AstraZeneca was posting earnings per share of £4.85. This is 1.75 times its current level of earnings of £2.77 and shows just how severe its demise has been.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

However, with AstraZeneca changing its strategy in recent years and deciding to go on the offensive so as to replace lost sales, its long term future has considerable potential. For example, it has purchased assets such as the other half of its diabetes joint venture with Bristol-Myers Squibb and this forms part of a repositioning of AstraZeneca, as it seeks to focus on illnesses and health problems that represent significant growth areas across the globe in the long run.

For instance, the number of Americans expected to have diabetes in 2050 is set to be 165% higher than in the year 2000, with this trend expected to be followed across much of the developed and developing world. This presents a tremendous opportunity for AstraZeneca to develop drugs to counter the effects of diabetes, with this being just one example of how the company’s pipeline looks set to benefit from being exposed to growth areas over the long run.


Despite its share price rise, AstraZeneca still offers good value for money. For example, it trades on a price to earnings (P/E) ratio of just 15.9, which is slightly below the FTSE 100’s P/E ratio of 16. And, while the next couple of years are expected to see its bottom line come under pressure, the company appears to be doing all of the right things to turn its performance around and is set to deliver growth from 2017 onwards.

Sector Peers

Clearly, there are a number of other top notch pharmaceutical companies within the FTSE 350. One prime example is BTG (LSE: BTG). It offers very different characteristics to AstraZeneca, with it being a strong growth play right now, with BTG’s bottom line expected to rise by 25% this year and by a further 50% next year. And, while it does trade on a P/E ratio of 35.7, its price to earnings growth (PEG) ratio of 0.5 indicates that its shares could move much higher.

Similarly, Genus (LSE: GNS) and Dechra (LSE: DPH) are expected to post excellent gains during the next two years. Their earnings are forecast to rise by 30% and 20% respectively during the period, although their PEG ratios of 1.9 and 2.2 respectively indicate that there is far less upside potential than for BTG. As such, BTG seems to be the pick of the three smaller companies.

However, with AstraZeneca’s pipeline on the up and the company having the potential to make further acquisitions, it remains a better buy than BTG. And, with AstraZeneca having bid potential of its own, as well as a very appealing valuation, its future performance could be superb and this makes it a very strong buy at the present time.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.